Aegle Therapeutics

Shelley Hartman, CEO

Oct. 11 | 11:45am | Oxford Biomedica Ballroom  

Woburn, MA 


In-person Presentation 

Aegle Therapeutics is a pioneer in the development of extracellular vesicle (EV) therapy. We are focused on rare diseases, including epidermolysis bullosa (EB), and burns. Aegle has a proprietary EV harvesting technology that is critical to the production of clinical grade product. Ours is a platform technology with potential indications including dermatology, immunology, and others. Aegle has been awarded Rare Pediatric Disease and Fast Track designation by the FDA for its EB indication. Aegle is seeking funding to launch its clinical trial in EB. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions